#1 Clinical Trials Search in Europe

Modified Mrna Encoding Human Methylmalonyl-Coenzyme A Mutase Containing A Polymorphism At Position 671

Clinical trials are underway to evaluate mRNA-3705, a novel gene therapy drug developed by Moderna for the treatment of methylmalonic acidemia (MMA) due to methylmalonyl-CoA mutase (MUT) deficiency. These trials aim to assess the safety, tolerability, and effectiveness of mRNA-3705 in patients with this rare genetic disorder. The studies involve both short-term and long-term evaluations of the drug’s impact on MMA symptoms, biomarkers, and quality of life for patients.

Table of Contents

What is mRNA-3705?

mRNA-3705 is an innovative medication being developed to treat a rare genetic disorder called methylmalonic acidemia (MMA). It is classified as a gene therapy, which means it aims to treat the underlying genetic cause of the disease[1]. The medication is also known by other names, including CX-020629[2].

What condition does mRNA-3705 treat?

mRNA-3705 is designed to treat isolated methylmalonic acidemia (MMA) due to methylmalonyl-CoA mutase (MUT) deficiency. MMA is a rare genetic disorder that affects the body’s ability to break down certain proteins and fats[1]. This leads to a buildup of toxic substances in the body, which can cause serious health problems.

How does mRNA-3705 work?

mRNA-3705 works by delivering genetic instructions to the body’s cells. These instructions help produce a functional version of the methylmalonyl-CoA mutase (MUT) enzyme, which is missing or defective in people with MMA. The medication uses a special delivery system called a lipid nanoparticle (LNP) to protect the genetic material and help it enter the cells[1][2].

Current Clinical Trials

mRNA-3705 is currently being studied in clinical trials to evaluate its safety and effectiveness. Two main studies are ongoing:

  1. A Phase 1/2 study to determine the best dose and dosing schedule for mRNA-3705[2].
  2. A long-term extension study to evaluate the safety and effectiveness of mRNA-3705 over an extended period[1].

Potential Benefits of mRNA-3705

Researchers are studying several potential benefits of mRNA-3705 for patients with MMA, including:

  • Reduction in levels of toxic substances in the blood, such as methylmalonic acid and 2-methylcitric acid (2-MC)[1][2].
  • Decrease in the frequency and severity of metabolic decompensation events (MDEs), which are serious health crises in MMA patients[1].
  • Reduction in MMA-related hospitalizations and urgent healthcare visits[1].
  • Improvement in quality of life and ability to tolerate more protein in the diet[2].

Safety Considerations

As with any new medication, safety is a primary concern. The clinical trials are closely monitoring for any side effects or adverse events. Some specific safety considerations include:

  • Monitoring for infusion-related reactions and hypersensitivity[2].
  • Checking for the development of antibodies against the treatment[1][2].
  • Assessing any impact on liver and kidney function[2].

Who is eligible for mRNA-3705 treatment?

Currently, mRNA-3705 is only available through clinical trials. Eligibility criteria include:

  • Confirmed diagnosis of isolated MMA due to MUT deficiency[2].
  • Age 1 year or older[2].
  • Body weight of at least 11 kg[2].
  • No history of liver or kidney transplant[1].
  • No previous gene therapy treatment for MMA[2].

Future Outlook

mRNA-3705 represents a promising new approach to treating MMA. If successful, it could potentially provide a long-term treatment option for patients with this rare genetic disorder. However, it’s important to note that the medication is still in the testing phase, and more research is needed to fully understand its effectiveness and safety profile[1][2].

Aspect Details
Drug Name mRNA-3705
Developer Moderna (ModernaTX, Inc.)
Target Condition Methylmalonic acidemia (MMA) due to methylmalonyl-CoA mutase (MUT) deficiency
Drug Type Gene therapy (modified mRNA encoding human MUT enzyme)
Administration Intravenous infusion
Trial Phases Phase 1/2
Primary Objectives Evaluate safety, tolerability, and efficacy in reducing metabolic decompensation events
Secondary Objectives Assess pharmacodynamics, pharmacokinetics, biomarker changes, quality of life improvements
Eligibility Patients ≥1 year old with confirmed MMA due to MUT deficiency, meeting specific clinical criteria
Study Duration Up to 154 weeks (including long-term follow-up)
Potential Benefits Reduction in toxic metabolites, fewer hospitalizations, improved quality of life

FAQ

  • What is mRNA-3705? mRNA-3705 is a gene therapy drug developed to treat methylmalonic acidemia (MMA) caused by methylmalonyl-CoA mutase (MUT) deficiency. It consists of modified mRNA encoding the human MUT enzyme, encapsulated in lipid nanoparticles for delivery to cells.
  • How is mRNA-3705 administered to patients? mRNA-3705 is administered to patients through intravenous (IV) infusion. This method allows the drug to be delivered directly into the bloodstream for distribution throughout the body.
  • What are the main objectives of the clinical trials for mRNA-3705? The main objectives of the clinical trials are to evaluate the safety and tolerability of mRNA-3705, assess its pharmacodynamic (PD) and pharmacokinetic (PK) properties, and determine its efficacy in reducing the frequency of metabolic decompensation events (MDEs) in patients with MMA.
  • Who is eligible to participate in these clinical trials? Eligible participants include individuals aged 1 year and older with a confirmed diagnosis of isolated MMA due to MUT deficiency. They must meet specific criteria regarding body weight, vitamin B12 levels, and clinical severity of MMA. Some trials also require a history of at least one MDE in the past year.
  • What are the potential benefits of mRNA-3705 for MMA patients? mRNA-3705 has the potential to reduce blood levels of methylmalonic acid and 2-methylcitrate (biomarkers of MMA), decrease the frequency of metabolic decompensation events and related hospitalizations, and improve overall quality of life for patients with MMA. The long-term studies aim to evaluate these benefits over an extended period.

Ongoing Clinical Trials on Modified Mrna Encoding Human Methylmalonyl-Coenzyme A Mutase Containing A Polymorphism At Position 671

  • Study on Long-Term Safety of mRNA-3705 for Patients with Methylmalonic Acidemia (MMA)

    Recruiting

    2 1 1 1
    Investigated drugs:
    France The Netherlands Spain

  • Study on mRNA-3705 for Patients with Methylmalonic Acidemia Due to Methylmalonyl-CoA Mutase Deficiency

    Not recruiting

    2 1
    Investigated drugs:
    France The Netherlands Spain

Glossary

  • Methylmalonic acidemia (MMA): A rare genetic disorder where the body cannot break down certain proteins and fats properly, leading to a buildup of toxic substances in the blood.
  • Methylmalonyl-CoA mutase (MUT): An enzyme that plays a crucial role in the breakdown of certain amino acids and odd-chain fatty acids. Deficiency in this enzyme causes MMA.
  • mRNA: Messenger RNA, a type of genetic material that carries instructions from DNA to make proteins in cells.
  • Lipid nanoparticle (LNP): A tiny particle made of fats that can be used to deliver drugs or genetic material into cells.
  • Pharmacodynamics (PD): The study of how a drug affects the body, including its mechanism of action and the body's response to the drug.
  • Pharmacokinetics (PK): The study of how the body processes a drug, including its absorption, distribution, metabolism, and excretion.
  • Metabolic decompensation event (MDE): A serious complication in MMA patients where their metabolic balance is disrupted, often leading to hospitalization.
  • Biomarker: A measurable substance in the body that can indicate the presence or severity of a disease or the effects of a treatment.
  • Gene therapy: A technique that uses genes to treat or prevent disease, often by replacing a faulty gene or introducing a new gene into the body.
  • Intravenous (IV) infusion: A method of delivering medications or fluids directly into a vein using a needle or catheter.

References

  1. http://clinicaltrials.eu/trial/study-on-long-term-safety-of-mrna-3705-for-patients-with-methylmalonic-acidemia-mma/
  2. http://clinicaltrials.eu/trial/study-on-mrna-3705-for-patients-with-methylmalonic-acidemia-due-to-methylmalonyl-coa-mutase-deficiency/